This article addresses some issues involved in meeting regulatory characterization expectations for biosimilars by answering the following questions: What regulatory guidelines are associated with structural characterization and comparability/biosimilarity testing? What complicates the characterization of complex (glyco)protein products? When is analytical characterization required? And which techniques (old and new) are suitable for this application?
![344 x 492 White Paper Primary](https://imgix-prod.sgs.com/-/media/sgscorp/images/old-do-not-reuse/white-paper-thumbnails/344-x-492-white-paper-primary.cdn.en-CZ.1.png?fit=clip&auto=format&w=1504)